# Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)

> **NCT03643952** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 18 (actual)

## Conditions studied

- Bacteremia
- Soft Tissue Infections
- Skin Diseases, Infectious

## Interventions

- **DRUG:** Daptomycin for Injection

## Key facts

- **NCT ID:** NCT03643952
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-06
- **Primary completion:** 2020-04-07
- **Final completion:** 2020-04-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03643952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03643952, "Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03643952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*